In this series, several crucial aspects of oligometastatic NSCLC lung cancer (OM-NSCLC) are covered, all pertinent to the management of OMD. We believe that some of this knowledge may become useful in the future for the management of stage IV lung cancer in general.
Editorial on Oligometastatic NSCLC: Definition and Treatment Opportunities
Oligometastatic non-small cell lung cancer: from biology to clinical practice
Local for advanced, is this a paradox?
Review Article on Oligometastatic NSCLC: Definition and Treatment Opportunities
Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review
Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis
Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review
The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review
Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review
Alternative methods for local ablation—interventional pulmonology: a narrative review
Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
Current and future research efforts in oligometastatic non-small cell lung cancer—a systematic review
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review
Disclosure:
The series “Oligometastatic NSCLC: definition and treatment opportunities” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Maurizio V. Infante and Thierry Berghmans served as the unpaid Guest Editors for the series.